Department of Molecular Oncology,
Cancer Research Institute,
Department of Molecular Oncology, Cancer Research Institute
Marina Cihova has not added Biography.
If you are Marina Cihova and would like to personalize this page please email our Author Liaison for assistance.
Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells.
Cancer letters Nov, 2017 | Pubmed ID: 28838843
Inflammation-Based Scores Increase the Prognostic Value of Circulating Tumor Cells in Primary Breast Cancer.
Cancers May, 2020 | Pubmed ID: 32369910
Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients.
International journal of molecular sciences Dec, 2020 | Pubmed ID: 33322711
Decreased levels of circulating cytokines VEGF, TNF-β and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients.
Scientific reports Jan, 2021 | Pubmed ID: 33446741
Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer.
Journal of experimental & clinical cancer research : CR Sep, 2021 | Pubmed ID: 34579743
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Mar, 2022 | Pubmed ID: 35091237
Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms.
Critical reviews in oncology/hematology Dec, 2022 | Pubmed ID: 36334880
Jesús Frutos Díaz-Alejo*,1,2,3,4,
Simon April-Monn*,5,
Marina Cihova6,
Verona Buocikova6,
Jorge Villalón López1,3,
Maria Urbanova6,
Carmen G. Lechuga7,
Miroslav Tomas6,8,
Peter Dubovan6,8,
Bárbara Luna Sánchez3,
Sonia Camaño Páez3,
Alfonso Sanjuanbenito2,9,
Eduardo Lobo9,
Estefanía Romio de la Heras10,
Carmen Guerra2,7,
Carolina de la Pinta11,
Emma Barreto Melian1,2,
Mercedes Rodríguez Garrote1,2,
Alfredo Carrato1,2,4,
Laura Ruiz-Cañas3,12,13,
Bruno Sainz, Jr.2,3,12,13,
Ana Torres3,
Bozena Smolkova6,
Julie Earl1,2,3
1Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS),
2, The Biomedical Research Network in Cancer (CIBERONC),
3Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS),
4Faculty of Medicine, University of Alcalá de Henares,
5Institute of Tissue Medicine and Pathology, University of Bern,
6Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences,
7Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO),
8Department of Surgical Oncology, National Cancer Institute, Slovak Medical University,
9Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal,
10Department of Pathology, Hospital Universitario Ramón y Cajal,
11Department of Radiation Oncology, Hospital Universitario Ramón y Cajal,
12Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM),
13Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved